Effectiveness of BA.1- and BA.4/BA.5-containing bivalent COVID-19 mRNA vaccines against symptomatic SARS-CoV-2 infection during the BA.5-dominant period in Japan
Takeshi Arashiro
;
Yuzo Arima;
Jin Kuramochi;
Hirokazu Muraoka;
Akihiro Sato;
Kumi Chubachi;
Atsushi Yanai;
Hiroko Arioka;
Yuki Uehara;
Genei Ihara;
+22 more...
Yasuyuki Kato;
Naoki Yanagisawa;
Akihiro Ueda;
Hideaki Kato
;
Hideaki Oka;
Yusuke Nishida;
Yuki Nidaira;
Takahiro Asami
;
Torahiko Jinta;
Akira Nakamura;
Kunihiro Oba;
Daisuke Taniyama;
Kei Yamamoto;
Katsushi Tanaka;
Kankuro Ueshima;
Tetsuji Fuwa;
Ashley Stucky;
Tadaki Suzuki;
Chris Smith
;
Martin Hibberd;
Koya Ariyoshi
;
Motoi Suzuki;
(2023)
Effectiveness of BA.1- and BA.4/BA.5-containing bivalent COVID-19 mRNA vaccines against symptomatic SARS-CoV-2 infection during the BA.5-dominant period in Japan.
Open forum infectious diseases.
ISSN 2328-8957
DOI: 10.1093/ofid/ofad240
In this multi-center prospective test-negative case-control study in Japan, the effectiveness of both BA.1-containing and BA.4/BA.5-containing bivalent COVID-19 mRNA vaccines against symptomatic infection during the BA.5-dominant period was high compared to no vaccination (65% and 76%) and moderate compared to monovalent vaccines administered over half a year before (46% combined).
Item Type | Article |
---|---|
Elements ID | 202550 |
Official URL | http://dx.doi.org/10.1093/ofid/ofad240 |
ORCID: https://orcid.org/0000-0002-5215-1500
ORCID: https://orcid.org/0000-0002-7853-5721
ORCID: https://orcid.org/0000-0002-8574-5989
ORCID: https://orcid.org/0000-0001-9238-3202
ORCID: https://orcid.org/0000-0002-1468-5296